RE: Tyk 2- BMS21 Dec 2019 09:23
Thanks Stoney. I think you highlighted my true question, they are phase 3 trials we are no where near phase 3 .at each advancement the npv will have a different discount rate so sar need to get data out or do a deal otherwise to me npv of different products has only a slight relevance. It’s like saying that Charlton academy is worth as much as man city academy because exceptional football players are worth millions and both academies have football players. If instead they said 3 players from Charlton academy are playing first team football at 17 and spurs are looking to buy them then I could understand the value of Charlton academy. Rubbish example but at least logic is there. I obviously don’t understand bio industry